Antibodies

24 Feb 2007 Avastin receives positive opinion in Europe for first-line treatment of women with metastatic breast cancer
23 Feb 2007 Significant Phase III Results with CIMZIA(TM) in Rheumatoid Arthritis
23 Feb 2007 New phase III study confirms positive outcome of Avastin in patients with advanced lung cancer
23 Feb 2007 Cell Genesys and Medarex Announce Encouraging Follow-Up Results from a Phase 1 Combination Therapy Trial With GVAX Immunotherapy for Prostate Cancer and Ipilimumab (MDX-010) Antibody
15 Feb 2007 Viventia Biotech provides update on cancer antibody clinical development programs
15 Feb 2007 Peregrine Pharmaceuticals Reports Positive Phase Ib Results for its Targeted Immunotherapy Bavituximab in Chronic Hepatitis C Infection
15 Feb 2007 DSM and Crucell announce breakthrough in the production of biopharmaceuticals with PER.C6(R) technology platform
14 Feb 2007 GlaxoSmithKline and Human Genome Sciences announce initiation of Phase 3 clinical trial of Lymphostat-B(R) in systemic lupus erythematosus
14 Feb 2007 Seattle Genetics Receives Orphan Drug Designations for its SGN-33 and SGN-35 Programs
14 Feb 2007 Boehringer Ingelheim and Xencor Enter into Antibody License and Commercialization Agreement
13 Feb 2007 BioInvent and ThromboGenics Receive Approval to Begin Clinical Trials for Anticoagulant TB-402
08 Feb 2007 Biogen Idec Initiates Randomized, Registrational Trial of Lumiliximab for Chronic Lymphocytic Leukemia
08 Feb 2007 Johnson & Johnson Psoriasis Drug CNTO 1275 Posts Mixed Results In Phase 2 Trial
07 Feb 2007 ImClone Systems Opts-out of Development Agreement with UCB to Focus Resources on Proprietary, Anti-VEGFr-2 Antibody IMC-1121B
06 Feb 2007 AstraZeneca Licenses Regeneron's Velocimmune(R) Technology For Discovering Human Monoclonal Antibodies
06 Feb 2007 Merck KGaA Seeks Approval for Erbitux for Colorectal Cancer in Japan
06 Feb 2007 UCB Licenses BioWa's POTELLIGENT(R) Technology for use in Antibody Research and Development
03 Feb 2007 Genentech Announces Positive Results from a Phase IV Study of Raptiva in Patients With Moderate-to-Severe Hand and Foot Psoriasis
02 Feb 2007 Overview On 2006 Sales Of TOP 20 Biologics To Be Released On February 26
26 Jan 2007 Biogen Idec Initiates Phase III Trial of Galiximab for Follicular Non-Hodgkin's Lymphoma
26 Jan 2007 Amgen's Fourth Quarter 2006 Revenue Increased 17% to $3.8 Billion; Full Year 2006 Revenue Increased 15% to $14.3 Billion
25 Jan 2007 Lucentis receives approval in the European Union - the first drug to improve vision in patients with wet AMD, a leading cause of blindness
25 Jan 2007 Kirin and Astellas Enter Into a Licensing Agreement on an Immunosuppressive Fully Human Monoclonal Antibody
25 Jan 2007 First Actemra multinational phase III trial demonstrates significant improvement in signs and symptoms of rheumatoid arthritis
24 Jan 2007 Medarex and Compugen Announce Therapeutic Antibody Co-Development Agreement

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top